- Home
- RMBI vs AGEN Comparison
RMBI vs AGEN Comparison
Compare RMBI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- AGEN
- Stock Information
- Founded
- RMBI 1887
- AGEN 1994
- Country
- RMBI United States
- AGEN United States
- Employees
- RMBI N/A
- AGEN N/A
- Industry
- RMBI Major Banks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMBI Finance
- AGEN Health Care
- Exchange
- RMBI Nasdaq
- AGEN Nasdaq
- Market Cap
- RMBI 140.3M
- AGEN 142.8M
- IPO Year
- RMBI 2019
- AGEN 2000
- Fundamental
- Price
- RMBI $14.63
- AGEN $4.64
- Analyst Decision
- RMBI
- AGEN Buy
- Analyst Count
- RMBI 0
- AGEN 2
- Target Price
- RMBI N/A
- AGEN $14.50
- AVG Volume (30 Days)
- RMBI 16.1K
- AGEN 387.0K
- Earning Date
- RMBI 10-23-2025
- AGEN 11-11-2025
- Dividend Yield
- RMBI 4.18%
- AGEN N/A
- EPS Growth
- RMBI 17.64
- AGEN N/A
- EPS
- RMBI 0.95
- AGEN N/A
- Revenue
- RMBI $43,502,862.00
- AGEN $101,706,000.00
- Revenue This Year
- RMBI N/A
- AGEN $26.25
- Revenue Next Year
- RMBI N/A
- AGEN N/A
- P/E Ratio
- RMBI $15.23
- AGEN N/A
- Revenue Growth
- RMBI 4.48
- AGEN N/A
- 52 Week Low
- RMBI $11.37
- AGEN $1.38
- 52 Week High
- RMBI $15.15
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- RMBI 50.83
- AGEN 49.61
- Support Level
- RMBI $14.33
- AGEN $4.36
- Resistance Level
- RMBI $14.66
- AGEN $5.20
- Average True Range (ATR)
- RMBI 0.35
- AGEN 0.28
- MACD
- RMBI -0.04
- AGEN 0.05
- Stochastic Oscillator
- RMBI 54.19
- AGEN 47.27
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).